amendment No. 3 to CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • November 3rd, 2022 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
This AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 27th day of July, 2022, by and among RIGEL PHARMACEUTICALS, INC., a Delaware corporation (“Rigel”), as a Borrower, MidCap FINANCIAL Trust, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
LICENSE AND transition services AGREEMENT by and between RIGEL PHARMACEUTICALS, INC., and Forma Therapeutics, Inc. July 27, 2022License and Transition Services Agreement • November 3rd, 2022 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LICENSE AND Transition services AGREEMENT (this “Agreement”), entered into as of July 27, 2022 (the “Effective Date”), is entered into by and between Rigel Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware (“Company”), and Forma Therapeutics, Inc. a corporation organized and existing under the laws of the state of Delaware (“Forma”).
